Formycon Overview
- Year Founded
-
1999
- Status
-
Public
- Employees
-
239
- Stock Symbol
-
FYB
- Investments
-
4
- Share Price
-
$55.04
- (As of Friday Closing)
Formycon General Information
Description
Formycon AG is a pharmaceutical company. It is engaged in the development of pharmaceutical and biopharmaceutical products and the development of drug delivery systems. Its focus is on treatments in ophthalmology and immunology as well as other chronic diseases. The company's pipeline in the biosimilar drugs category includes FYB201, FYB202, FYB203, and FYB207 for the treatment of COVID-19. It is also engaged in the provision of diagnostic laboratory services and works for third parties and the carrying out of diagnostic laboratory services.
Contact Information
Website
www.formycon.comCorporate Office
- Fraunhoferstrasse 15
- Planegg
- 82152 Martinsried
- Germany
Corporate Office
- Fraunhoferstrasse 15
- Planegg
- 82152 Martinsried
- Germany
Formycon Timeline
Formycon Stock Performance
As of 06-Dec-2024, Formycon’s stock price is $55.04. Its current market cap is $972M with 17.7M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $55.04 | $53.72 | $40.13 - $64.09 | $972M | 17.7M | 4.71K | $4.40 |
Formycon Financials Summary
As of 30-Jun-2024, Formycon has a trailing 12-month revenue of $65.8M.
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 982,098 | 971,413 | 1,379,202 | 699,120 |
| Revenue | 65,780 | 84,073 | 44,681 | 43,287 |
| EBITDA | 66,542 | 84,640 | 40,249 | (14,847) |
| Net Income | 69,131 | 82,016 | 37,842 | (15,713) |
| Total Assets | 1,015,930 | 984,206 | 915,503 | 80,065 |
| Total Debt | 11,645 | 32,594 | 31,431 | 5,982 |
Formycon Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Formycon Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Formycon Patents
Formycon Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4386084-A1 | Improved ace2 fusion proteins | Pending | 14-Dec-2022 | ||
| EP-4331571-A1 | Formulations of ace2-igm fusion proteins | Pending | 02-Sep-2022 | ||
| EP-4437112-A1 | Improved ace2 fusion proteins | Pending | 24-Nov-2021 | ||
| EP-4377452-A2 | Ace2 fusion proteins and uses thereof | Pending | 30-Jul-2021 | ||
| CA-3220545-A1 | Formulations of anti-pd1 antibodies | Pending | 23-Jun-2021 | C07K16/2818 |
Formycon Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Formycon Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Formycon Investments & Acquisitions (4)
Formycon’s most recent deal was a Merger/Acquisition with Bioeq (Zug) for . The deal was made on 10-May-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Bioeq (Zug) | 10-May-2022 | Merger/Acquisition | Pharmaceuticals | ||
| FYB 202 | 01-May-2022 | Merger/Acquisition | Biotechnology | ||
| FYB 202 | 22-Dec-2017 | Joint Venture | Biotechnology | ||
| Scil Technology (R&D & Service Units) | 31-Dec-2011 | Merger/Acquisition | Discovery Tools (Healthcare) |
Formycon ESG
Risk Overview
Risk Rating
Updated April, 24, 2024
26.95 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,100
Rank
Percentile
Pharmaceuticals
Industry
of 851
Rank
Percentile
Biotechnology
Subindustry
of 367
Rank
Percentile
Formycon FAQs
-
When was Formycon founded?
Formycon was founded in 1999.
-
Where is Formycon headquartered?
Formycon is headquartered in Martinsried, Germany.
-
What is the size of Formycon?
Formycon has 239 total employees.
-
What industry is Formycon in?
Formycon’s primary industry is Pharmaceuticals.
-
Is Formycon a private or public company?
Formycon is a Public company.
-
What is Formycon’s stock symbol?
The ticker symbol for Formycon is FYB.
-
What is the current stock price of Formycon?
As of 06-Dec-2024 the stock price of Formycon is $55.04.
-
What is the current market cap of Formycon?
The current market capitalization of Formycon is $972M.
-
What is Formycon’s current revenue?
The trailing twelve month revenue for Formycon is $65.8M.
-
What is Formycon’s annual earnings per share (EPS)?
Formycon’s EPS for 12 months was $4.40.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
